

July 13, 2021



# Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer

Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- [Lixte Biotechnology Holdings, Inc. \(Nasdaq: LIXT\)](#) ("Lixte" or the "Company") noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine's Cancer Biology program, was selected for the second time to receive the National Latino Leader Award and a scholarship to present virtually studies of LB-100 in triple negative breast cancer (TNBC) at the 2021 Society of Advancing Chicanos/Hispanics and Native Americans in the Sciences Conference, October 25-29, 2021. His recognition notes significant research accomplishments despite the challenges posed by the COVID 19 pandemic.

Lixte congratulates Pimentel and his coauthors on their demonstration that LB-100 significantly inhibits the growth of TNBC cells, whether they are resistant or sensitive to the anti-tumor agent TRAIL (tumor necrosis factor related apoptosis-inducing ligand). It was noted that LB-100 sensitizes TNBC cells to the chemotherapeutic drugs, paclitaxel and cisplatin, which are commonly used for the treatment of TNBC. Pimentel and his coauthors concluded that their data suggest that inhibition of PP2A activity could be a novel therapeutic approach to this notoriously unresponsive sub-type of breast cancer ([Uddin, Pimentel et al, Cell Cycle 2020](#)).

Lixte's CEO John S. Kovach, MD commented, "Preclinical studies at leading medical centers have shown that LB-100 enhances standard therapies for many cancers, including some of the most aggressive types. The report from Wayne State University is a good example of this phenomenon. Lixte is currently focused on demonstrating the effectiveness of LB-100 in other cancers where better therapies are also urgently needed, and would welcome a partner interested in evaluating LB-100 as a component of chemotherapy for TNBC. There is a clear need for such a therapy, as TNBC comprises 15-20 % of all breast cancers, the most common malignancy and a leading cause of cancer death among women in the US."

## **About Lixte Biotechnology Holdings, Inc.**

[Lixte Biotechnology Holdings, Inc. \(Nasdaq:LIXT\)](#) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients.

Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemotherapy or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. Additional information can be obtained at the Company's website at [www.lixte.com](http://www.lixte.com).

## **Forward-Looking Statements**

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," "anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at [sec.gov/edgar.shtml](http://sec.gov/edgar.shtml).

## **Lixte Contact:**

[info@lixte.com](mailto:info@lixte.com)

General Phone: (631) 830-7092

Investor Phone: (888) 289-5533



Source: Lixte Biotechnology Holdings, Inc.